DAX20.917 +0,1%ESt505.155 +0,1%Top 10 Crypto17,25 +4,1%Dow43.488 +0,8%Nas19.630 +1,5%Bitcoin104.594 +6,0%Euro1,0314 +0,4%Öl80,42 -0,4%Gold2.708 +0,2%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
ByteDance BYT111 NVIDIA 918422 Rheinmetall 703000 Tesla A1CX3T Trump Media Technology A3CYXD Bayer BAY001 Commerzbank CBK100 Novo Nordisk A3EU6F Deutsche Bank 514000 MicroStrategy 722713 Siemens Energy ENER6Y Allianz 840400 BASF BASF11 Mercedes-Benz Group (ex Daimler) 710000 Amazon 906866
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Trumps Amtsantritt könnte 21.000-er Marke möglich machen: DAX mit neuem Rekord -- Gewinne in Asien -- Neuer Bitcoin-Rekord -- Commerzbank vor Jobabbau -- Rheinmetall, Formycon, Siemens Energy im Fokus
Top News
Siemens Energy-Aktie wird abgestraft: UBS senkt Siemens Energy auf 'Sell' - 'Priced for perfection' Siemens Energy-Aktie wird abgestraft: UBS senkt Siemens Energy auf 'Sell' - 'Priced for perfection'
Bitcoin steigt kurz vor Trumps Amtseinführung auf Rekordhoch Bitcoin steigt kurz vor Trumps Amtseinführung auf Rekordhoch
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil
Wer­bung
Wenn Krypto, dann Bitpanda. Jetzt sicher in Bitcoin investieren.

Novo Nordisk Aktie

NeuKaufenVerkaufen
Aktien-Sparplan anlegen
76,94 EUR -0,29 EUR -0,38 %
STU
77,00 EUR -0,01 EUR -0,01 %
GVIE
Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!
JETZT LOSLEGEN
Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handelnSmartphone

Marktkap.340,49 Mrd. EUR

KGV37,40Div. Rendite1,35%

WKNA3EU6F

ISINDK0062498333

SymbolNONOF

Novo Nordisk Aktien News

DatumMeistgelesen
GlobeNewswireNovo Nordisk A/S: Semaglutide 7.2 mg s.c. achieved 20.7% weight loss in the STEP UP obesity trial, and 18.7% regardless of treatment adherence
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireValo Health and Novo Nordisk expand collaboration to discover and develop novel treatments for cardiometabolic diseases
Wer­bungNovo Nordisk-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: CagriSema demonstrates superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial
GlobeNewswireThe acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is completed
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk invests DKK 8.5 billion in new production facility in Odense, Denmark
GlobeNewswireNovo Nordisk A/S: The acquisition of Catalent by Novo Holdings, and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings, is cleared to close
GlobeNewswireNovo Nordisk A/S: European regulatory authority adopts positive opinion for an update of the Ozempic® label to reflect risk reduction of kidney disease-related events
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireThe European Commission approves the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S purchases B shares worth DKK 4,736 million from Novo Holdings A/S under the 2024 share repurchase programme
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
GlobeNewswireNovo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024
GlobeNewswireNovo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: Oral semaglutide demonstrates a 14% reduction in risk of major adverse cardiovascular events in adults with type 2 diabetes in the SOUL trial
GlobeNewswireNovo Nordisk A/S: Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk launches new initiative to prevent childhood obesity in disadvantaged urban communities
GlobeNewswireNovo Nordisk A/S – Share repurchase programme
GlobeNewswireNovo Nordisk A/S – Share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
GlobeNewswireNovo Nordisk A/S: Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
GlobeNewswireNovo Nordisk A/S - share repurchase programme
GlobeNewswireNovo Nordisk A/S - share repurchase programme
Wer­bung

Novo Nordisk News

Novo Nordisk News: auf dieser Seite finden Sie alle Novo Nordisk News und Nachrichten zur Novo Nordisk Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novo Nordisk News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novo Nordisk News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.